Core Viewpoint - Changchun High-tech has entered into an exclusive licensing agreement with Yarrow for the GenSci098 injection project, receiving an initial payment of $70 million, which enhances the company's cash reserves and supports its future R&D and internationalization strategy [1][4]. Group 1: Licensing Agreement Details - The agreement allows Yarrow to have global exclusive rights for the development, production, and commercialization of GenSci098 injection outside Greater China, specifically targeting thyroid-related eye disease (TED) and Graves' disease (GD) [3]. - Changchun High-tech's subsidiary, SaiZeng Medical, retains the rights for development and commercialization of GenSci098 in China [3]. Group 2: Product Information - GenSci098 is a humanized monoclonal antibody designed to treat hyperthyroidism by blocking the synthesis and release of thyroid hormones and preventing the proliferation of thyroid cells [2]. - The injection has shown potential in preclinical data and ongoing Phase I clinical trials for TED, with plans for further clinical development targeting GD [2]. Group 3: Financial Implications - SaiZeng Medical is expected to receive a total of $120 million in upfront and milestone payments, including the initial $70 million and an additional $50 million for recent development milestones [4]. - The agreement also includes potential milestone payments of up to $1.365 billion and over 10% sales royalties post-product launch [4].

Core Viewpoint - Changchun Gaoxin has received a $70 million upfront payment from Yarrow Bioscience for the exclusive licensing agreement related to the GenSci098 injection project, enhancing the company's cash reserves and supporting its future R&D and international strategy [1] Group 1 - Changchun Gaoxin's subsidiary, Changchun Jinsai Pharmaceutical, has a wholly-owned subsidiary, Shanghai Saizeng Medical Technology, which entered into an exclusive licensing agreement with Yarrow Bioscience for the GenSci098 injection project [1] - The agreement grants Yarrow exclusive rights to develop, produce, and commercialize GenSci098 injection globally, excluding Greater China [1] - The payment received will further strengthen the company's cash reserves and assist in advancing its pipeline development and international strategy [1]

Reinstatement - Zhite New Materials and *ST Chengchang have completed their suspension investigations and their stocks have resumed trading [1][1] Share Buybacks and Equity Transfers - Hongli Zhihui's Mr. Li Guoping plans to transfer 5% of shares at a price of 5.93 CNY per share [2] - Luxshare Precision plans to repurchase company shares for between 1 billion to 2 billion CNY [2] - Defu Technology intends to repurchase shares for between 75 million to 150 million CNY, with a maximum repurchase price of 53.46 CNY per share [2] External Investments and Daily Operations - Hanyu Pharmaceutical has signed a sales order for GLP-1 raw materials worth 180 million CNY, which accounts for 30.50% of its audited revenue for 2024 [3] - Defu Technology plans to acquire a 26.32% stake in Amber New Materials for 509.5 million CNY [4] - Changchun High-tech has received a one-time payment of 70 million USD from Yarrow for the exclusive licensing agreement related to the GenSci098 injection project [4] - Zhongchuang Zhiling plans to issue convertible bonds to raise no more than 4.35 billion CNY for various high-end manufacturing projects [4] - Triangle Tire intends to invest 3.219 billion CNY to establish a new company in Cambodia for the production of 7 million high-performance radial tires annually [4] - Zhejiang Zhongtuo's subsidiary Hunan Zhongtuo has been selected as a restructuring investor for Jiangsu Delong Nickel Industry and 30 other companies [4] Performance Changes - Tianji Co. expects a net profit of 70 million to 105 million CNY in 2025, with a recovery in profitability due to rising sales prices of lithium hexafluorophosphate [5] - SAIC Group anticipates a net profit of 9 billion to 11 billion CNY in 2025, representing a year-on-year increase of 438% to 558% [6] - Shengnuo Bio expects a net profit of 152 million to 190 million CNY in 2025, a year-on-year increase of 204.42% to 280.53% [6] - Zhenghai Magnetic Materials forecasts a net profit of 310 million to 380 million CNY in 2025, with a year-on-year increase of 235.72% to 311.52% [6] - Sanmei Co. expects a net profit of 1.99 billion to 2.15 billion CNY in 2025, a year-on-year increase of 155.66% to 176.11% [6] - Tongxing Technology anticipates a net profit of 68 million to 88 million CNY in 2025, a year-on-year increase of 74.2% to 125.44% [7] - Luoyang Molybdenum expects a net profit of 20 billion to 20.8 billion CNY in 2025, a year-on-year increase of 47.80% to 53.71% [8] - Nawei Technology forecasts a net profit of 12.8 million to 14.5 million CNY in 2025, a year-on-year increase of 54.51% to 75.03% [9]

Core Viewpoint - Changchun High-tech (000661) has made progress in the GenSci098 injection project by signing an exclusive licensing agreement, receiving an initial payment of $70 million from Yarrow [1] Group 1: Company Developments - The company's subsidiary, Jinsai Pharmaceutical, through its wholly-owned subsidiary, Saizeng Medical, has entered into an exclusive licensing agreement with Yarrow for the GenSci098 injection project [1] - GenSci098 injection is a humanized TSH receptor antagonist monoclonal antibody developed by Jinsai Pharmaceutical, classified as a first-class new drug for therapeutic biological products [1]

证券代码：000661 证券简称：长春高新 公告编号：2026-003 长春高新技术产业（集团）股份有限公司 关于 GenSci098 注射液项目签署独家许可协议的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 重要提示： 二、有关 GenSci098 注射液项目 1 GenSci098 注射液是金赛药业自主研发的一种人源化促甲状腺激素受体 （TSHR）拮抗型单克隆抗体，为治疗用生物制品 1 类新药。通过特异性与甲状 腺或球后组织内 TSHR 结合，阻断其与自身抗体结合，进而抑制甲状腺激素的合 成和释放、抑制甲状腺细胞的增殖、阻止 HA 和炎症因子释放，从而发挥改善甲 亢的作用，并同时具有改善突眼的作用。本品临床前数据、在研的甲状腺眼病 （TED）的 I 期临床研究以及同靶点其他药物的临床数据表明，GenSci098 有潜 力作为一种治疗弥漫性毒性甲状腺肿的新型治疗手段，相关临床试验可以推动后 续该产品针对弥漫性毒性甲状腺肿人群的临床开发。 目前，GenSci098 注射液已于 2024 年 8 月同步在中国大陆及美国获批开展 用于甲状腺相关眼病（T ...

Core Viewpoint - The company has received a significant upfront payment of $70 million from Yarrow Bioscience for the exclusive licensing agreement related to the GenSci098 injection project, which is set to undergo clinical trials for thyroid-related eye disease and Graves' disease in China and the United States [1] Group 1 - The company’s subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., has a wholly-owned subsidiary, Shanghai Saizeng Medical Technology Co., Ltd., which is involved in the licensing agreement [1] - The GenSci098 injection has been approved to commence clinical trials for thyroid eye disease (TED) in both mainland China and the United States starting August 2024 [1] - The injection is also set to be approved for clinical trials for Graves' disease (GD) in mainland China by October 2025 [1]

Core Viewpoint - Changchun High-tech announced that its subsidiary, Jinsai Pharmaceutical, has signed an exclusive licensing agreement with Yarrow for the GenSci098 injection project, which will enhance the company's cash reserves and support its pipeline development and international strategy [1] Group 1 - The exclusive licensing agreement was signed on December 15, 2025, granting Yarrow global exclusive development rights for GenSci098 injection outside of Greater China [1] - The first payment of $70 million is expected to be received on January 14, 2026, although the actual amount will be subject to taxes and fees [1] - GenSci098 injection is a self-developed product by Jinsai Pharmaceutical, which has already been approved for clinical trials in both China and the United States [1]

Group 1 - The core issue raised by investors is the reported shortage of Changchun High-tech's long-acting growth hormone after its inclusion in the medical insurance system [1] - Changchun High-tech responded by stating that it will manage the delivery of products based on market demand and price changes [1]

Core Viewpoint - Changchun Gaoxin (000661) stated that the company will reasonably arrange shipments based on market demand and product price changes [1] Group 1 - The company is actively engaging with investors through an interactive platform [1] - The company emphasizes the importance of market demand in its operational decisions [1] - Product price fluctuations will also influence the company's shipment arrangements [1]

2026年1月6日，九泰基金发布公告称，基金经理刘开运因工作调整离任九泰锐和18个月定开混合基金。 | 离任基金经理姓名 | 刘开运 | | --- | --- | | 离任原因 | 因工作调整 | | 离任日期 | 2026-1-6 | | 是否转任本公司其他工作岗位 | 否 | | 是否己按规定在中国基金业协会办理变更手续 | 是 | 九泰锐和18个月定开混合基金三季报显示，该基金在三季度重点新买入北方华创、龙佰集团、博源化工、盾安环境等，重点卖出贝达药业、长春高新。 九泰锐和18个月定开混合基金三季报中指出，博源化工在报告编制日前一年内曾受到金融监管总局的处罚，对以上证券的投资决策程序符合法律法规及公司 制度的相关规定，不存在损害基金份额持有人利益的行为。 风险提示：观点仅供参考，不构成投资建议，市场有风险，投资需谨慎。基金过往业绩不代表未来表现，基金管理人及基金经理管理的其他基金的业绩并不 构成对本基金业绩表现。 九泰锐和18个月定开混合基金成立于2020年12月，自成立以来刘开运便一直管理该基金，刚成立时的净认购金额约为2.04亿元，到了2025年三季度末，资产 净值约为972.4万元。 九泰锐和1 ...